89260-46-8

Basic information

• Product Name: 3-(1H-PYRAZOL-3-YL)ANILINE
• Synonyms: 3-(1H-PYRAZOL-3-YL)ANILINE;3-(1H-pyrazol-5-yl)aniline(SALTDATA: FREE);3-(1H-pyrazol-5-yl)aniline;Benzenamine, 3-(1H-pyrazol-3-yl)-;3-(2H-Pyrazol-3-yl)-phenylamine;[3-(1H-Pyrazol-5-yl)phenyl]amine
• CAS NO: 89260-46-8
• Molecular Formula: C₉H₉N₃
• Molecular Weight: 159.19
• Mol File: 89260-46-8.mol

Chemical Properties

• Boiling Point: 442.3 °C at 760 mmHg
• Flash Point: 251.5 °C
• Appearance: /
• Density: 1.238 g/cm³
• Vapor Pressure: 5.1E-08mmHg at 25°C
• Refractive Index: 1.662
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-(1H-PYRAZOL-3-YL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1H-PYRAZOL-3-YL)ANILINE(89260-46-8)
• EPA Substance Registry System: 3-(1H-PYRAZOL-3-YL)ANILINE(89260-46-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 89260-46-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-(1H-Pyrazol-3-yl)aniline is used as a key intermediate in the synthesis of biologically active molecules for pharmaceutical applications, leveraging its unique structure to create compounds with potential therapeutic effects.
Used in Anti-Inflammatory Applications:
3-(1H-Pyrazol-3-yl)aniline is utilized as an anti-inflammatory agent, where its chemical properties contribute to reducing inflammation and associated symptoms, offering a potential treatment for various inflammatory conditions.
Used in Anticancer Applications:
In the field of oncology, 3-(1H-Pyrazol-3-yl)aniline is employed as an anticancer agent, where its molecular structure may interact with cellular targets to inhibit cancer cell growth and proliferation, providing a potential therapeutic strategy against various types of cancer.
Used in Dye and Pigment Production:
3-(1H-Pyrazol-3-yl)aniline is used as a precursor in the manufacturing of dyes and pigments, capitalizing on its chemical properties to produce a range of colorants for various industrial applications.
Used in Medicinal Chemistry:
3-(1H-Pyrazol-3-yl)aniline plays a crucial role in medicinal chemistry, serving as a building block for the development of new drugs and therapeutic agents, particularly in the areas of inflammation and cancer treatment.

InChI:InChI=1/C9H9N3/c10-8-3-1-2-7(6-8)9-4-5-11-12-9/h1-6H,10H2,(H,11,12)

Upstream product

• 89260-45-7 4-(1H-Pyrazol-3-yl)aniline 
• 20583-31-7 3-(4-nitrophenyl)-1H-pyrazole 
• 59843-77-5 5-(3-nitrophenyl)-1H-pyrazole 
• 54060-30-9 3-acetylenephenylamine 
• 73789-56-7 N-isocyaniminotriphenylphosphorane 
• 59843-77-5 1-(1H-pyrazol-3-yl)-3-nitrobenzene 

Downstream Products

• 1114591-87-5 6-[(cyclopropylmethyl)(propyl)amino]-N-[3-(1H-pyrazol-3-yl)phenyl]pyrimidine-4-carboxamide 
• 1240521-76-9 C₂₂H₂₁N₅OS 
• 1240521-75-8 C₁₈H₁₈N₄O 
• 1401206-82-3 C₂₃H₂₆N₄O₃ 
• 1240521-75-8 (2S)-N-(3-(1H-pyrazol-3-yl)phenyl)-2-amino-3-phenylpropanamide 
• 1240521-76-9 (2S)-N-(3-(1H-pyrazol-3-yl)phenyl)-3-phenyl-2-(thiazol-4-ylmethylamino)propanamide 

Relevant articles and documents

Molybdenum-silver co-catalyzed cycloaddition of alkynes with: N -isocyanoiminotriphenylphosphorane (NIITP): An efficient strategy for the synthesis of monosubstituted pyrazoles

A new molybdenum-silver co-catalyzed [3+2] cycloaddition of alkynes with N-isocyanoiminotriphenylphosphorane (NIITP) has been described. The NIITP serves as a non-toxic, facile "CNN" source. Over 30 substrates were successfully converted to the desired compounds in good to excellent yields.

Silver-Mediated [3 + 2] Cycloaddition of Alkynes and N-Isocyanoiminotriphenylphosphorane: Access to Monosubstituted Pyrazoles

A silver-mediated [3 + 2] cycloaddition of "CNN" and "C≡C" for constructing pyrazoles has been described. The "CNN" building block used is N-isocyanoiminotriphenylphosphorane, which is a stable, safe, easy-to-handle, and odorless solid isocyanide. The reaction is characterized by its mild conditions, broad substrate scope, and excellent functional group tolerance.

Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus

The discovery and initial optimization of a series of phenylalanine based agonists for GPR142 is described. The structure-activity-relationship around the major areas of the molecule was explored to give agonists 90 times more potent than the initial HTS hit in a human GPR142 inositol phosphate accumulation assay. Removal of CYP inhibition by exploration of the pyridine A-ring is also described.

PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS

Provided herein are compounds of formula I: wherein A, B, X, R1 , R2 and subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions

SUBSTITUTED HETEROCYCLYL-PHENYLFORMAMIDINES AND SALTS THEREOF

Compounds of the formula STR1 wherein R is hydrogen or methyl;R 1 is straight or branched alkyl of 1 to 6 carbon atoms, hydroxy(alkyl of 1 to 6 carbon atoms), mono-or di-(alkoxy of 1 to 6 carbon atoms)(alkyl of 1 to 6 carbon atoms), (alkyl of 1 to 6 cabon atoms) thio(alkyl of 1 to 6 carbon atoms), cyano(alkyl of 1 to 6 carbon atoms), alkenyl, alkynyl, or cycloalkyl;R 2 is hydrogen, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms or halogen; andX is pyrazol-3-yl, 1,2,4-triazol-3-yl, pyridin-2-yl, pyridin-3-yl, thiazol-4-yl, 2-methyl-thiazol-4-yl or 2-methylamino-thiazol-4-yl;tautomers thereof, and non-toxic, pharmacologiically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antiulcerogenics and gastric acid secretion inhibitors.